Compare Dicks Sporting Goods Inc (DKS) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dicks Sporting Goods Inc vs Incyte Corporation — how do they compare? Dicks Sporting Goods Inc trades at $203.48 (market cap $18.35B), while Incyte Corporation trades at $120.58 (market cap $24.54B). The key difference: Incyte Corporation is the larger of the two by market cap, and Dicks Sporting Goods Inc pays a 2.44% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| DKS | INCY | |
|---|---|---|
Market Cap | $18.35B | $24.54B |
Sector | Consumer Cyclical | Health |
52-Week High | $239.17 | $129.93 |
52-Week Low | $187.78 | $81.61 |
Enterprise Value | $25.14B | $20.04B |
Dividend Yield | 2.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DKS trades at $203.44, down 4.98% on the day, amid a bearish technical signal. The company has consistently beaten earnings estimates in recent quarters, with strong profitability metrics including a 20.9% ROE and 4.71% net income margin. Analyst consensus is strongly bullish with a $263.22 price target and no sell ratings. Recent news highlights include positive coverage from Zacks and an upcoming Q2 2026 earnings call on August 25th.
The outlook remains positive given strong fundamentals and analyst support, but risks include competitive pressures and the stock's current bearish technical trend. The key near-term catalyst is the Q2 earnings report, which could validate the bullish sentiment if results meet or exceed the expected EPS of $3.77.
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
